N30 Pharma has successfully completed Phase 1 study of N30-201 in healthy volunteers. N30 intends to develop N30-201 for the treatment of reactive and obstructive airway diseases, including Cystic Fibrosis and asthma.
"We are pleased to have begun and completed the first set of human studies of N30-201. We believe that N30-201 could be an important therapy for the treatment of many respiratory diseases. Determining the safety of acute administration of N30-201 to human subjects is the first step," commented Charles Scoggin, M.D., Chairman of N30 Pharma.